TMDX TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.…
Industry Peers
Medical DevicesKey Statistics
About TransMedics Group (NASDAQ: TMDX)
›
TransMedics Group (NASDAQ: TMDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 898 employees.
The shares were at 85.25 USD on 20 November 2026, down 31.8% over 52 weeks. Its 52-week range is 60.10 USD to 156.00 USD: the price is 45.4% below the high and 41.8% above the low.
At a market capitalisation of 2.96B USD, it trades at 23.2 times trailing earnings and 34.3 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, so TMDX is valued in line with them.
TransMedics Group reports return on equity of 40.2%, an operating margin of 11.9% and revenue up 41.1% year over year.
Its debt exceeds its cash by 373.94M USD, a debt-to-equity ratio of 1.10. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 105.45 USD is 23.7% above the current price. The next earnings report is expected on 1 March 2027.